As published in Shine, China’s based Shanghai Chest Hospital is leading the clinical trial for a Chinese-developed drug targeting one type of lung cancer. Another 33 hospitals are participating in the nationwide study. The study is expected to wrap up before the end of 2019. Thereafter the sponsor will seek regulatory approval for use.
According to the recent press from China, currently there are no drugs specifically targeting patients with MET exon 14 skipping mutation. It is found in about 3 percent of lung cancer patients. Dr Lu Shun of Shanghai Chest Hospital reports “both Chinese and Western medical experts are conducting research targeting this mutation and our clinical trial of the new targeted medicine has received considerable attention from the international medical community.” Dr. Shun continued “Current clinical trials saw positive responses in 55% of patients, whose average survival is expected to prolong from eight months to two years.”
Dr Lu Shun of Shanghai Chest Hospital